Hill , A G , Findlay , M , Burge , M , Jackson , C , Garcia Alfonso , P , Samuel , L , Ganju , V , Karthaus , M , Amatu , A , Jeffrey , M , Di Bartolomeo , M , Bridgewater , J , Coveler , A , Hidalgo , M , Kapp , A , Sufan , R , McCall , B , Hanley , W , Penuel , E , Pirzkall , A & Tabernero , J 2018 , ' Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer ' , Clinical Cancer Research , vol. 24 , no. 10 , pp. 2276-2284 . https://doi.org/10.1158/1078-0432.CCR-17-0646